Hazel B Nichols1, Mariaelisa Graff2, Jeannette T Bensen2, Kathryn L Lunetta3, Katie M O'Brien4, Melissa A Troester2, Lindsay A Williams5, Kristin Young2, Chi-Chen Hong6, Song Yao6, Christopher A Haiman7, Edward A Ruiz-Narváez8, Christine B Ambrosone6, Julie R Palmer3, Andrew F Olshan2. 1. Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 2104F McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA. hazel.nichols@unc.edu. 2. Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 2104F McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA. 3. Slone Epidemiology Center, Boston University, 72 E Concord Street, Boston, MA, 02118, USA. 4. Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, NC, USA. 5. Department of Pediatrics, University of Minnesota, 2450 Riverside Avenue, Minneapolis, MN, 55454, USA. 6. Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. 7. Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. 8. Department of Nutritional Sciences, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Abstract
PURPOSE: Circulating anti-Müllerian hormone (AMH) levels are positively associated with time to menopause and breast cancer risk. We examined breast cancer associations with single nucleotide polymorphisms (SNPs) in the AMH gene or its receptor genes, ACVR1 and AMHR2, among African American women. METHODS: In the AMBER consortium, we tested 65 candidate SNPs, and 1130 total variants, in or near AMH, ACVR1, and AMHR2 and breast cancer risk. Overall, 3649 cases and 4230 controls contributed to analyses. Odds ratios (OR) and 95% confidence intervals (CI) for breast cancer were calculated using multivariable logistic regression. RESULTS: After correction for multiple comparisons (false-discovery rate of 5%), there were no statistically significant associations with breast cancer risk. Without correction for multiple testing, four candidate SNPs in ACVR1 and one near AMH were associated with breast cancer risk. In ACVR1, rs13395576[C] was associated with lower breast cancer risk overall (OR 0.84; 95% CI 0.72, 0.97) and for ER+ disease (OR 0.75; CI 0.62, 0.89) (p < 0.05). Rs1220110[A] and rs1220134[T] each had ORs of 0.89-0.90 for postmenopausal and ER+ breast cancer (p ≤ 0.03). Conversely, rs1682130[T] was associated with higher risk of ER+ breast cancer (OR 1.17; 95% CI 1.04, 1.32). Near AMH, rs6510652[T] had ORs of 0.85-0.90 for breast cancer overall and after menopause (p ≤ 0.02). CONCLUSIONS: The present results, from a large study of African American women, provide limited support for an association between AMH-related polymorphisms and breast cancer risk and require replication in other studies.
PURPOSE: Circulating anti-Müllerian hormone (AMH) levels are positively associated with time to menopause and breast cancer risk. We examined breast cancer associations with single nucleotide polymorphisms (SNPs) in the AMH gene or its receptor genes, ACVR1 and AMHR2, among African American women. METHODS: In the AMBER consortium, we tested 65 candidate SNPs, and 1130 total variants, in or near AMH, ACVR1, and AMHR2 and breast cancer risk. Overall, 3649 cases and 4230 controls contributed to analyses. Odds ratios (OR) and 95% confidence intervals (CI) for breast cancer were calculated using multivariable logistic regression. RESULTS: After correction for multiple comparisons (false-discovery rate of 5%), there were no statistically significant associations with breast cancer risk. Without correction for multiple testing, four candidate SNPs in ACVR1 and one near AMH were associated with breast cancer risk. In ACVR1, rs13395576[C] was associated with lower breast cancer risk overall (OR 0.84; 95% CI 0.72, 0.97) and for ER+ disease (OR 0.75; CI 0.62, 0.89) (p < 0.05). Rs1220110[A] and rs1220134[T] each had ORs of 0.89-0.90 for postmenopausal and ER+ breast cancer (p ≤ 0.03). Conversely, rs1682130[T] was associated with higher risk of ER+ breast cancer (OR 1.17; 95% CI 1.04, 1.32). Near AMH, rs6510652[T] had ORs of 0.85-0.90 for breast cancer overall and after menopause (p ≤ 0.02). CONCLUSIONS: The present results, from a large study of African American women, provide limited support for an association between AMH-related polymorphisms and breast cancer risk and require replication in other studies.
Entities:
Keywords:
Anti-Müllerian hormone; Breast cancer; Case–control; Genetic polymorphisms
Authors: Marlies Voorhuis; Frank J Broekmans; Bart C J M Fauser; N Charlotte Onland-Moret; Yvonne T van der Schouw Journal: J Clin Endocrinol Metab Date: 2010-12-30 Impact factor: 5.958
Authors: A Heather Eliassen; Anne Zeleniuch-Jacquotte; Bernard Rosner; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-03-09 Impact factor: 4.254
Authors: Marlies E Kevenaar; Axel P N Themmen; Anke J van Kerkwijk; Olivier Valkenburg; André G Uitterlinden; Frank H de Jong; Joop S E Laven; Jenny A Visser Journal: Hum Reprod Date: 2008-10-14 Impact factor: 6.918
Authors: Linda T Roten; Matthew P Johnson; Siri Forsmo; Elizabeth Fitzpatrick; Thomas D Dyer; Shaun P Brennecke; John Blangero; Eric K Moses; Rigmor Austgulen Journal: Eur J Hum Genet Date: 2008-09-10 Impact factor: 4.246
Authors: Stephen A Haddad; Edward A Ruiz-Narváez; Christopher A Haiman; Lara E Sucheston-Campbell; Jeannette T Bensen; Qianqian Zhu; Song Liu; Song Yao; Elisa V Bandera; Lynn Rosenberg; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer; Kathryn L Lunetta Journal: Carcinogenesis Date: 2016-06-07 Impact factor: 4.944
Authors: Martha L Slattery; Esther M John; Gabriela Torres-Mejia; Jennifer S Herrick; Anna R Giuliano; Kathy B Baumgartner; Lisa M Hines; Roger K Wolff Journal: Int J Cancer Date: 2012-12-13 Impact factor: 7.396
Authors: Elisa V Bandera; Urmila Chandran; Gary Zirpoli; Susan E McCann; Gregory Ciupak; Christine B Ambrosone Journal: BMC Med Res Methodol Date: 2013-05-31 Impact factor: 4.615